Travere Therapeutics (NASDAQ:TVTX) Posts Earnings Results, Beats Estimates By $0.29 EPS

Travere Therapeutics (NASDAQ:TVTX) posted its quarterly earnings data on Monday. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29, FiscalAI reports. Travere Therapeutics had a negative return on equity of 28.38% and a negative net margin of 4.00%.The company had revenue of $127.20 million for the quarter, compared to analyst estimates of $136.23 million. During the same period in the previous year, the firm earned ($0.47) earnings per share. The firm’s quarterly revenue was up 55.6% on a year-over-year basis.

Here are the key takeaways from Travere Therapeutics’ conference call:

• First FDA approval for Filspari in FSGS — establishes Filspari as the first and only approved medicine for FSGS, expanding the U.S. addressable population (company cites >30,000 FSGS patients and >100,000 across IgAN/FSGS) and underpinning a stated ~$3 billion potential peak sales opportunity.
• Strong commercial momentum with record demand in IgA nephropathy (993 new patient start forms in Q1) and Filspari U.S. revenue of $105.2 million (?88% YoY growth), plus early signs of faster uptake and initial payer approvals in the FSGS launch.
• Pipeline progress on pegtibatinase — enrollment has restarted in the pivotal Phase III HARMONY study and the first post-restart patient was dosed, with top-line results expected in the second half of 2027 and the program positioned as a potential first disease-modifying therapy for classical HCU (addressable ~7,000–10,000 globally).
• Operating costs and certain non-cash expenses rose meaningfully (R&D $57.1M; SG&A $80.3M; royalty expense $24.8M), the GAAP net loss was $37.1M (non?GAAP net income $4.1M), and the company disclosed cash, marketable securities and receivables of ?$352M (cash ?$264.7M), which investors may watch closely given increased investment for launches and the Phase III program.

Travere Therapeutics Stock Down 0.2%

Travere Therapeutics stock traded down $0.08 during trading on Wednesday, hitting $44.72. 1,604,180 shares of the company were exchanged, compared to its average volume of 2,156,230. The business’s 50 day moving average is $32.31 and its 200 day moving average is $32.71. Travere Therapeutics has a 52 week low of $13.88 and a 52 week high of $48.61. The company has a market capitalization of $4.13 billion, a P/E ratio of -194.50 and a beta of 1.13. The company has a current ratio of 2.74, a quick ratio of 2.70 and a debt-to-equity ratio of 2.71.

Insider Transactions at Travere Therapeutics

In other Travere Therapeutics news, insider Elizabeth E. Reed sold 44,715 shares of the company’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $41.21, for a total value of $1,842,705.15. Following the completion of the transaction, the insider owned 111,996 shares in the company, valued at $4,615,355.16. This represents a 28.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider William E. Rote sold 9,100 shares of the company’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $39.09, for a total value of $355,719.00. Following the completion of the transaction, the insider owned 113,987 shares of the company’s stock, valued at $4,455,751.83. This trade represents a 7.39% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 310,852 shares of company stock worth $11,890,666. Company insiders own 4.44% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. State Street Corp grew its stake in Travere Therapeutics by 47.8% in the 4th quarter. State Street Corp now owns 4,756,666 shares of the company’s stock valued at $181,752,000 after purchasing an additional 1,538,827 shares during the period. Adage Capital Partners GP L.L.C. grew its stake in Travere Therapeutics by 27.4% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company’s stock valued at $41,203,000 after purchasing an additional 599,102 shares during the period. Renaissance Technologies LLC grew its stake in Travere Therapeutics by 28.2% in the 4th quarter. Renaissance Technologies LLC now owns 2,246,779 shares of the company’s stock valued at $85,849,000 after purchasing an additional 494,665 shares during the period. Rock Springs Capital Management LP grew its stake in shares of Travere Therapeutics by 2.1% during the 4th quarter. Rock Springs Capital Management LP now owns 2,210,322 shares of the company’s stock worth $84,456,000 after acquiring an additional 45,549 shares during the period. Finally, Wellington Management Group LLP grew its stake in shares of Travere Therapeutics by 3,331.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,201,469 shares of the company’s stock worth $28,715,000 after acquiring an additional 1,166,460 shares during the period.

Analyst Ratings Changes

Several equities analysts have issued reports on TVTX shares. Canaccord Genuity Group boosted their price target on Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a research note on Tuesday, April 14th. TD Cowen boosted their price target on Travere Therapeutics from $45.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday. Guggenheim boosted their price target on Travere Therapeutics from $54.00 to $56.00 and gave the company a “buy” rating in a research note on Friday, April 24th. HC Wainwright boosted their price target on Travere Therapeutics from $47.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Wall Street Zen lowered Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $47.83.

Travere Therapeutics News Roundup

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Wells Fargo raised its price target to $50 and upgraded TVTX to “Overweight,” giving the stock fresh upside from current levels. Wells Fargo Price Target Raise
• Positive Sentiment: TD Cowen lifted its target sharply to $60 and maintained a “Buy” — another bullish analyst action that supports upside expectations tied to Travere’s pipeline and commercial execution. TD Cowen Price Target Raise
• Positive Sentiment: Q1 results showed an EPS beat (reported $0.05 vs. consensus -$0.24) and management highlighted FILSPARI approval in FSGS, strong demand and progress on pegtibatinase — positives for revenue growth and long?term value if commercial momentum continues. Q1 Results & Corporate Update
• Neutral Sentiment: HC Wainwright reiterated a “Buy” and long?term EPS runway (FY2027–FY2030 forecasts show multi?year growth), supporting the bullish thesis despite small model adjustments. HC Wainwright Estimates
• Neutral Sentiment: Investors can review the Q1 earnings call transcript for management commentary on commercial traction and pipeline timelines. Earnings Call Transcript
• Negative Sentiment: Revenue missed expectations ($127.2M reported vs. ~$136.2M consensus) and some outlets flagged a quarterly loss/miss on revenue — a near?term headwind that likely pressured the stock despite the EPS beat. Revenue Miss Coverage
• Negative Sentiment: HC Wainwright trimmed FY2027–FY2030 EPS estimates slightly (minor cuts across years). While small, these revisions reduce near?term model momentum and may temper upside expectations. HC Wainwright Estimate Revisions
• Negative Sentiment: Director Roy Baynes sold 9,750 shares under a pre?arranged 10b5?1 plan (filed with the SEC); insider sales can be viewed negatively by some investors, even if pre?planned. SEC Filing: Insider Sale

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.